Xenetic Biosciences, Inc. (NASDAQ:XBIO)

PRESS RELEASE

published on 07/23/2025 at 14:30, 6 months 28 days ago

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences expands research collaboration with TSRI to validate DNase-I data in lymphoma and leukemia models. Advancing oncology therapies with CAR T-cells

Xenetic Biosciences Research Collaboration Leukemia Lymphoma DNase-I Data
BRIEF

published on 07/08/2025 at 15:05, 7 months 12 days ago

Xenetic Biosciences Updates on DNase I Study Collaboration

Xenetic Biosciences Clinical Study Pancreatic Cancer DNase I FOLFIRINOX
BRIEF

published on 07/08/2025 at 15:05, 7 months 12 days ago

Xenetic Biosciences met à jour sa collaboration sur l'étude de la DNase I

Étude Clinique Biosciences Xénétiques Cancer Du Pancréas ADNase I FOLFIRINOX
PRESS RELEASE

published on 07/08/2025 at 15:00, 7 months 12 days ago

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C
Xenetic Biosciences, Inc. announces exploratory clinical study in Israel evaluating DNase I with FOLFIRINOX for pancreatic cancer treatment

Xenetic Biosciences Pancreatic Cancer DNase I FOLFIRINOX Exploratory Clinical Study
BRIEF

published on 05/14/2025 at 14:10, 9 months 6 days ago

Xenetic Biosciences publie ses résultats financiers du premier trimestre 2025

Résultats Financiers Partenariats Stratégiques Augmentation Des Revenus Programme DNase I Collaboration Avec PeriNess
BRIEF

published on 05/14/2025 at 14:10, 9 months 6 days ago

Xenetic Biosciences Reports Q1 2025 Financial Results

Financial Results Strategic Partnerships Revenue Increase DNase I Program Collaboration With PeriNess
PRESS RELEASE

published on 05/14/2025 at 14:05, 9 months 6 days ago

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. focuses on strategic exploratory clinical studies with partners, progressing DNase I program, and reported $5.2 million cash for operations

Financial Results Xenetic Biosciences Immuno-oncology Clinical Studies DNase I
BRIEF

published on 04/09/2025 at 15:20, 10 months 11 days ago

Xenetic Biosciences Shares Promising Preclinical Data at SITC Meeting

Xenetic Biosciences Preclinical Data Solid Tumors DNase Technology CAR-T Cell Therapy
BRIEF

published on 04/09/2025 at 15:20, 10 months 11 days ago

Xenetic Biosciences partage des données précliniques prometteuses lors de la réunion du SITC

Biosciences Xénétiques Thérapie Cellulaire CAR-T Tumeurs Solides Données Précliniques Technologie DNase
PRESS RELEASE

published on 04/09/2025 at 15:15, 10 months 11 days ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette of Xenetic presents positive preclinical data on DNase I intervention enhancing CAR-T cell therapy in solid tumors at SITC 2025 Cell Therapy Meeting. Learn more at Xenetic's website

Immuno-oncology Xenetic DNase I SITC 2025 CAR-T Cell Therapy

Published on 02/20/2026 at 21:40, 32 minutes ago

IBC Advanced Alloys Announces Closing of Initial US$1,250,000 Funding by The Lind Partners
Published on 02/20/2026 at 20:15, 1 hour 57 minutes ago

Lithium South Announces Results of its Annual and Special Meeting of Securityholders
Published on 02/20/2026 at 20:15, 1 hour 57 minutes ago

Verdera Energy Announces Closing of Qualifying Transaction
Published on 02/20/2026 at 18:30, 3 hours 42 minutes ago

Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 6 hours 27 minutes ago

Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway

View all ACCESSWIRE

Published on 02/20/2026 at 18:36, 3 hours 36 minutes ago

EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 3 hours 41 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:23, 3 hours 49 minutes ago

POS-Transaction in Own Shares
Published on 02/20/2026 at 18:00, 4 hours 12 minutes ago

Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 4 hours 12 minutes ago

Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations

View all EQS

Published on 02/20/2026 at 19:29, 2 hours 43 minutes ago

SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 19:29, 2 hours 43 minutes ago

SFPI GROUP: bilan du contrat de liquidité S2 S025
Published on 02/20/2026 at 18:00, 4 hours 12 minutes ago

TERACT - Termination of liquidity agreement
Published on 02/20/2026 at 18:00, 4 hours 12 minutes ago

TERACT - Résiliation du contrat de liquidité
Published on 02/20/2026 at 17:35, 4 hours 37 minutes ago

CHIFFRE D'AFFAIRES 2025

View all LES ECHOS COMFI WIRE

News